| dc.contributor.author | Ramdas, Sithara | |
| dc.contributor.author | Painho, Teresa | |
| dc.contributor.author | Vanegas, Maria I | |
| dc.contributor.author | Famili, Dennis T | |
| dc.contributor.author | Lim, Ming J | |
| dc.contributor.author | Jungbluth, Heinz | |
| dc.date.accessioned | 2025-07-25T14:35:31Z | |
| dc.date.available | 2025-07-25T14:35:31Z | |
| dc.date.issued | 2024-11 | |
| dc.description.abstract | Myasthenia gravis (MG) is an antibody-mediated disorder of the neuromuscular junction affecting children and adults. MG is a treatable condition with most patients requiring immunosuppression for disease control and/or remission. Juvenile myasthenia gravis (JMG) is rare in comparison with adult-onset MG but given the same underlying pathophysiology, treatment strategies are similar to those in adults. Until recently, there were only a few randomised controlled trials (RCTs) for MG treatments in adults and none in children, and management strategies were primarily based on expert consensus. In addition, treatment options for refractory MG cases have been severely limited, resulting in poor long-term quality of life in such patients due to the significant disease burden. Recently, there have been several RCTs focussing on novel therapeutic strategies with potentially promising outcomes, suggesting a change in MG management over the coming years and access to more effective and faster-acting drugs for MG patients. This paper will review current and new MG treatments including efgartigimod, eculizumab, rozanolixizumab, ravulizumab, and zilucoplan, with a focus on juvenile myasthenia gravis. | |
| dc.identifier.citation | Paediatr Drugs . 2024 Nov;26(6):719-740 | |
| dc.identifier.doi | 10.1007/s40272-024-00649-3 | |
| dc.identifier.other | 39198371 | |
| dc.identifier.uri | http://hdl.handle.net/10400.17/5128 | |
| dc.language.iso | en | |
| dc.peerreviewed | yes | |
| dc.publisher | Springerlink | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | |
| dc.subject | Adolescent | |
| dc.subject | Child | |
| dc.subject | Myasthenia Gravis* / drug therapy | |
| dc.subject | Myasthenia Gravis* / physiopathology | |
| dc.subject | Myasthenia Gravis* / therapy | |
| dc.subject | Quality of Life | |
| dc.subject | HDE NEU PED | |
| dc.title | Targeted Treatments for Myasthenia Gravis in Children and Adolescents. | |
| dc.type | text | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 740 | |
| oaire.citation.issue | 6 | |
| oaire.citation.startPage | 719 | |
| oaire.citation.volume | 26 | |
| oaire.version | http://purl.org/coar/version/c_970fb48d4fbd8a85 |
